Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tarih
2019
Yazar
Lubiniecki, Gregory M.
Lopes, Gilberto
Kubota, Kaoru
Zhang, Jin
Kush, Debra
Mok, Tony S. K.
Wu, Yi-Long
Kudaba, Iveta
Kowalski, Dariusz M.
Cho, Byoung Chul
Turna, Hande Z.
Castro, Gilberto
Srimuninnimit, Vichien
Laktionov, Konstantin K.
Bondarenko, Igor
Üst veri
Tüm öğe kaydını göster
Özet
Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.
Bağlantı
http://hdl.handle.net/20.500.12627/118579
https://doi.org/10.1016/s0140-6736(18)32409-7
Koleksiyonlar